Altimmune Inc (ALT)

$9.09 0.17 (1.84%)

13:00 EST ALT Stock Quote Delayed 30 Minutes

Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data

By William White, InvestorPlace Writer Sep 14, 2022

Altimune (ALT) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning.

7 Biotech Stocks to Buy for Q3

ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap 446.86M

PE Ratio -4.78

EPS -1.9

Volume (Avg. Vol.) 337,905

Day's Range $8.87 - $9.29

52-Week Range $3.83 - $23.49

Dividend & Yield N/A (N/A)

ALT Stock Predictions, Articles, and Altimmune Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer May 10, 2021

Get ready for another busy week of trading as we kick off Monday with a look at the biggest pre-market stock movers for today.

2020 In Review — 9 Great (And Not-So-Great) Calls

By Chris Lau, InvestorPlace Contributor Jan 6, 2021

Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.

Altimmune Earnings: ALT Stock Rises 7% Despite Rough Q2 Results

By Nick Clarkson, Web Editor Aug 12, 2020

Altimmune earnings from Tuesday evening have ALT stock higher despite the company reporting rough figures for second quarter of FY2020.

Altimmune Earnings: ALT Stock Tumbles 12% on FY Miss

By William White, InvestorPlace Writer Mar 27, 2020

Altimmune (ALT) earnings for the biopharmaceutical company's fiscal year of 2019 have ALT stock taking a dive Friday after missing estimates.

Altimmune Stock Has Major Pipeline Potential

By Louis Navellier and the InvestorPlace Research Staff Mar 18, 2020

There's no guarantee of a coronavirus cure, but Altimmune stock is worth owning on hopes of an effective vaccine.

Altimmune News: ALT Stock Rockets 110% on Coronavirus Vaccine News

By William White, InvestorPlace Writer Feb 28, 2020

Altimmune (ALT) news for Monday includes positive news about a vaccine to treat the coronavirus from China have ALT stock soaring higher.

Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

By William White, InvestorPlace Writer Mar 19, 2019

Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.

Why Altimmune Stock Is Sliding Lower Today

By William White, InvestorPlace Writer Oct 8, 2018

Altimmune stock was falling hard Monday on news that the company is selling additional stock to investors in a new offering.

Why Altimmune Stock Is Skyrocketing Today

By Karl Utermohlen, InvestorPlace Writer Sep 19, 2018

Altimmune stock (ALT) soared more than 285% following successful clinical trial data of a medication and a reverse split of common shares.

My 3 Top Biotech Stock Picks for 2023

From The Motley Fool Nov 22, 2022

Biotech stocks are set to shine in 2023.

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), 89bio (ETNB) and Avadel Pharmaceuticals (AVDL)

From TipRanks Nov 21, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Inhibrx (INBX)

From TipRanks Nov 18, 2022

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (

Altimmune rises 5.2% on smaller-than-expected Q3 loss (NASDAQ:ALT)

From Seeking Alpha Nov 10, 2022

Altimmune (ALT) is trading 5.2% higher after the company posted narrower-than-expected Q3 loss. Revenue was minimal for the three months, compared to $0.2 million, a year ago, due to...

Altimmune GAAP EPS of -$0.48 beats by $0.01 (NASDAQ:ALT)

From Seeking Alpha Nov 10, 2022

Altimmune press release (ALT): Q3 GAAP EPS of -$0.48 beats by $0.01.Altimmune had cash, cash equivalents and short-term investments totaling $201.9 million at September 30,...

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

From TipRanks Nov 8, 2022

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT – Research Report), with a price target of $26.00....

Altimmune Inc (ALT)

Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data

7 Biotech Stocks to Buy for Q3

ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

11 Best Stocks to Buy for 2022

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Altimmune Inc (ALT)

11 Best Stocks to Buy for 2022

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ALT Stock Predictions, Articles, and Altimmune Inc News

Subscriber Sign in